Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Chronic inflammatory demyelinating polyneuropathy


Other Names for this Disease

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • CIDP
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Overview

What is Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?

How might chronic inflammatory demyelinating polyneuropathy (CIDP) be treated?

What is the long-term outlook for people with chronic inflammatory demyelinating polyneuropathy (CIDP)?

What is Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disorder is caused by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibers) of the peripheral nerves. It often presents with symptoms that include tingling or numbness (beginning in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes, fatigue, and abnormal sensations. CIDP is closely related to Guillain-Barre syndrome and it is considered the chronic counterpart of that acute disease. Treatment may include corticosteroids, immunosuppressant drugs, plasma exchange, physiotherapy, and/or intravenous immunoglobulin (IVIg) therapy.[1]
Last updated: 8/1/2012

How might chronic inflammatory demyelinating polyneuropathy (CIDP) be treated?

Treatment for CIDP includes:[1][2]  

 

  • Corticosteroids such as prednisone to help reduce inflammation and relieve symptoms
  • Medications that suppress the immune system (azathioprine, methotrexate, mycophenolate, cyclosporine, and cyclophosphamide)
  • Removal of antibodies from the blood through plasmapheresis or plasma exchange
  • Intravenous immunoglobulin (IVIg) therapy, which adds large numbers of antibodies to the blood plasma to reduce the effect of the antibodies 
  • Physiotherapy to improve muscle strength, function and mobility, and minimize the shrinkage of muscles and tendons and distortions of the joints

 

Detailed information about management options can be accessed through the Treatment and Medication sections of Medscape Reference.
Last updated: 8/1/2012

What is the long-term outlook for people with chronic inflammatory demyelinating polyneuropathy (CIDP)?

The course of CIDP varies widely among individuals. Some may have a bout of CIDP followed by spontaneous recovery, while others may have many bouts with partial recovery in between relapses. The disease is a treatable cause of acquired neuropathy and initiation of early treatment to prevent loss of nerve axons is recommended. However, some individuals are left with some residual numbness or weakness.[1]
Last updated: 8/1/2012

References
  1. NINDS Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Information Page. National Institute of Neurological Disorders and Stroke (NINDS). 2011; http://www.ninds.nih.gov/disorders/cidp/cidp.htm. Accessed 8/1/2012.
  2. Chronic inflammatory polyneuropathy. MedlinePlus. 2010; http://www.nlm.nih.gov/medlineplus/ency/article/000777.htm. Accessed 8/1/2012.


Other Names for this Disease
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • CIDP
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.